

CURRICULUM VITAE

A. Personal Information:

Name	Noah M Merin, MD/PhD
Business Address	Division of Hematology, Blood and Marrow Transplantation Program Cedars-Sinai Medical Center 8700 Beverly Blvd, Suite AC1046 Los Angeles, CA 90048
Business Phone	(310) 423-3157
Business Fax	(310) 423-0446
E-Mail Address	Noah.merin@cshs.org

B. Education:

College or University	Wesleyan University, CN, Neuroscience, BA, 1998
Graduate School	University of California, Davis, Davis, CA, Neuroscience, PhD, 2008
Medical School	University of California, Davis, Davis, CA, MD, 2008
Internship	University of California, Davis Medical Center, Sacramento, CA, Internal Medicine, 2009
Residency	Harbor-UCLA, Torrance, CA, Internal Medicine, 2012
Fellowship	University of Southern California, Los Angeles, CA, Hematology, 2015
Honors and Awards	Chief Fellow, USC Division of Hematology, 2014
Medical Licensure	A110852, CA, 2010
Board Certification	Internal Medicine, 2012 Hematology, 2015 Medical Oncology, 2015

C. Professional Background:

Academic Appointments

Attending, Staff Physician I, Cedars-Sinai Blood and Marrow Transplantation
Program 8/2016 -

Clinical Instructor, USC/Norris Cancer Hospital, Division of Hematology, Los
Angeles, CA, 7/2015 - 6/2016

Specific Teaching Responsibilities

Instructor, Medical School Hematology Year II, 2015 - 2016

D. Society Memberships:

Professional

American Society of Clinical Oncology, 2012

American Association for Cancer Research 2012

American Society of Hematology 2013

American Society for Blood and Marrow Transplantation 2015

E. Research Activities:

Major Areas of Research Interest

Immune System & Cancer; Haploidentical Stem Cell Transplantation;
Transplantation for Lymphoid Malignancies

Research in Progress

Profiling of Patient Immune Responses to Soluble EphB4-HSA; Microtransplantation
for AML

Research Grants

1. CIRM Training Grant Clinical Fellow, TG2-01161, CIRM, \$ 82,800
Clinical Fellow, 2014 - 2016 +Fringe
Post-doctoral Training Grant provides salary support and ~
\$8,000 for supplies / travel. 75% effort.

F. Clinical Trials:

1. PhII-134, Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy
2. A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To Or Relapsed after First-Line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

3. A Phase 1b Study of REOLYSIN® combined with Standard Doses of Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
4. Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects with Refractory or Relapsed Lymphoma or Multiple Myeloma
5. A Phase I/IIA Multi-Dose Escalation Study Of BT062 In Combination With Lenalidomide Or Pomalidomide And Dexamethasone In Subjects With Relapsed Or Relapsed/Refractory Multiple Myeloma
6. Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
7. A Multi-Center, Open-Label, Phase 1/1B Study Of Escalating Doses Of RO5503781 Administered Orally As 1) A Single Agent, 2) In Combination With Cytarabine, Or 3) With Cytarabine And Anthracycline In Patients With Acute Myelogenous Leukemia (AML)
8. A Phase IB/II Study Evaluating The Safety, Tolerability And Anti-Tumor Activity Of Polatuzumab Vedotin (DCDS4501A) In Combination With Rituximab (R) Or Obinutuzumab (G) Plus Bendamustine (B) In Relapsed Or Refractory Follicular Or Diffuse Large B-Cell Lymphoma
9. A Phase IB/II Multi-Arm Study With Venetoclax In Combination With Cobimetinib And Venetoclax In Combination With Idasanutlin In Patients Aged ≥60 Years With Relapsed Or Refractory Acute Myeloid Leukemia Who Are Not Eligible For Cytotoxic Therapy

G. Bibliography:

Peer Reviewed

Manning BH, **Noah M. Merin**, Meng ID, Amaral DG. “Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex.” J Neurosci. 2001 Oct 15;21(20):8238-46.

Natalie Pageler, Vinod Menon, **Noah M. Merin**, Stephan Eliez, Wendy E. Brown, and Allan L. Reiss. “Effect of head orientation on gaze processing in fusiform gyrus and superior temporal sulcus.” Neuroimage 2003 Sep;20(1):318-29

Noah M. Merin, Gregory S. Young, Sally Ozonoff, and Sally Rogers. "Visual Fixation Patterns during Reciprocal Social Interaction Distinguish a Subgroup of 6-Month-Old Infants At-Risk for Autism from Comparison Infants." *J Autism Dev Disord*. 2007 Jan;37(1):108-21.

Gregory S. Young, **Noah M. Merin**, Sally Ozonoff, Sally Rogers. "Gaze behavior and affect at 6 months: predicting clinical outcomes and language development in typically developing infants and infants at risk for autism." *Developmental Science*. 2009 Sep;12(5):798-814.

Merin NM, Kelly KR. "Clinical use of proteasome inhibitors in the treatment of multiple myeloma." *Pharmaceuticals (Basel)*. 2014 Dec 24;8(1):1-20.

Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, **Merin NM**, Pinski J. "Effects of luteinizing hormone receptor signaling in prostate cancer cells." *Prostate*. 2015 Feb;75(2):141-50.

Non Peer Reviewed

Noah M. Merin, Joel Steele, David Whitney, Gregory Young, Sally Ozonoff, and Sally J. Rogers. "Oculomotor Smooth Pursuit in Infants and Toddlers At-Risk for Autism." Dissertation Chapter

Noah M. Merin, Joel Steele, David Whitney, Gregory Young, Sally Ozonoff, and Sally J. Rogers. "Visual Tracking is Abnormal in 24-Month-Old Children with Autism." Dissertation Chapter

Poster Sessions

Noah M. Merin, V. Menon, C. D. White, G. H. Glover, A. L. Reiss. "Gaze Processing Deficits in Fragile X Syndrome Investigated Using fMRI." Poster, Cognitive Neuroscience Society Meeting 2000

Noah M. Merin, Gregory S. Young, Sally Ozonoff, and Sally Rogers. "Visual fixation patterns during reciprocal social interaction distinguish a subgroup of 6-month-old infants at-risk for autism from comparison infants." Poster, Society for Neuroscience Meeting 2006

Noah M. Merin, C.E. Thirkill, John Keltner. "Paraneoplastic Optic Neuropathy (PON) and Cancer Associated Retinopathy (CAR) Syndromes: New Findings" Poster, North American Neuro-Ophthalmological Society Meeting, 2008.

Noah M. Merin, Darrell Harrington. “Renal Vein Thrombosis and Septic Pulmonary Emboli Due to Acute Pyelonephritis.” Poster, American College of Physicians 2010 Southern California Region I Chapter Scientific Meeting

Noah M. Merin, James Yeh. “Familial Adenomatous Polyposis Complicated by Mesenteric Fibromatosis.” Poster, UCLA Solomon’s Scholars Symposium 2010.